Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

2280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2030-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC). Women living with HIV (WLWH) have a six-fold higher risk of developing precancerous lesions that persist and progress to CC, which is the leading cause of cancer mortality among women in Kenya. Significant support from the Go Further campaign, represented by donors such as the President's Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, UNAIDS, Merck, and Roche, to integrate CC screening into HIV clinics represents an exceptional opportunity to scale CC impact across SSA, but only if implementation science evidence is available to inform strategy. Currently, the impact of Go Further has been undermined by fractured linkages to care and insensitive screening methods; in Kenya, less than 2% of WLWH screened have received appropriate treatment. Implementation science studies are needed to better understand and surmount barriers to integrated care in publicly funded HIV clinics.

Broad objective This study seeks to explore and innovate strategies to overcome patient-, provider-, and system-level barriers to implementing CC screening and referral guidelines, link WLWH who require further diagnostic testing and/or treatment with effective and accessible care, and document services for accountability and quality improvement. In this proposal, our team will apply our extensive implementation science expertise and partnerships with Kenya Ministry of Health (MOH) to adapt and test evidence-based strategies (e.g., HPV self-testing, care navigators, and the WEMA mHealth app \[tested and scaled in Tanzania\]) that address key multi-level barriers identified through a formative, stakeholder-engaged research phase.

Methodology Using the EPIS framework to guide our project, we will: Aim 1a), Explore (engage a multi-disciplinary stakeholder advisory board to co-design the intervention package and prioritize implementation strategies that align with local capacity, opportunities, and motivations; Aim 1b), Prepare (develop tools and strengthen capacity at clinics to implement the strategies; Aim 2), Implement and evaluate the package of implementation strategies via a cluster-randomized stepped wedge trial in 9 clinics (assessing implementation \[provision of CC screening with HPV self-testing\] and effectiveness \[proportion of HPVpositive WLWH who receive subsequent diagnostic triage and/or treatment\] over months 0-12; and Aim 3), assess Sustainability (costs, cost-effectiveness, and transfer of delivery from study to local staff over months 13-18.

Significance of the study The overall goal of this study is to employ rigorous empirical methods to adapt and test implementation strategies that expand the scope of HIV care to screen for and treat early precancerous CC lesions in a sustainable, scalable way. Through partnering with Kenya's MOH, this project will have critical institutional support and dissemination capability, and will directly inform public health practice and policy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Broad Objectives This study seeks to inform the effective and sustainable integration of early detection and successful treatment of precancerous cervical lesions among women living with HIV (WLWH) ages 25-49 years in HIV care clinics for women in Kenya.

Specific Objectives I. Identify and address barriers to integration and uptake of cervical cancer screening and treatment linkage in HIV care settings in Kenya.

II. Evaluate the implementation and effectiveness of ENHANCE LINKage (HPV self-testing, care navigators, and mHealth that supports screening and treatment linkage) in a hybrid type 2 study, a cluster randomized trial in 20 HIV care clinics.

III. Evaluate sustainability and economic impacts of ENHANCE LINKage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection Human Papillomavirus-Related Cervical Carcinoma Screening Strategy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

hybrid type 2 implementation-effectiveness cluster randomized clinical trial

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aim 2, Arm I (ENHANCE LINKAge)

Patients receive HPV self-testing kit and instruction on how to perform HPV self-testing on study. Patients undergo vaginal self-swab and receive results by text message. Patients also receive mobile text message reminders for triage or treatment for women that test positive with HPV.

Group Type EXPERIMENTAL

Health Promotion and Education

Intervention Type OTHER

Receive instructions on how to use HPV self-testing kit

HPV Self-Collection

Intervention Type PROCEDURE

Undergo HPV self-collection

Text Message-Based Navigation Intervention

Intervention Type OTHER

Receive text messages for HPV testing results and triage and treatment reminders

Aim 2 (standard care)

Patients undergo standard of care at clinics that have VIA testing

Group Type ACTIVE_COMPARATOR

Best Practice

Intervention Type OTHER

Receive standard care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Best Practice

Receive standard care

Intervention Type OTHER

Health Promotion and Education

Receive instructions on how to use HPV self-testing kit

Intervention Type OTHER

HPV Self-Collection

Undergo HPV self-collection

Intervention Type PROCEDURE

Text Message-Based Navigation Intervention

Receive text messages for HPV testing results and triage and treatment reminders

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard of care standard therapy At-home HPV Self Collection HPV Self Collection Human Papillomavirus Self-Collection Automated Text Message-Based Navigation Text Message-Based Navigation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AIM 1 (PATIENTS): Aged 25-49 years
* AIM 1 (PATIENTS): Female
* AIM 1 (PATIENTS): Willing to participate in a 90-minute audio-recorded focus group discussion (FGD) and
* AIM 1 (PATIENTS): Speak English or Swahili
* AIM 1 (NURSES, CLINICAL STAFF, ADMINISTRATORS): Aged 18 years or older
* AIM 1 (NURSES, CLINICAL STAFF, ADMINISTRATORS): Involved in implementing intervention components
* AIM 1 (STAKEHOLDERS): Adults (aged \>= 18 years) who are healthcare system users, support persons, healthcare providers and administrators, representatives of the government, professional associations, and non-governmental and faith-based organizations
* AIMS 2 AND 3 (CLINIC PROVIDERS): Aged 18 years and older involved in CC screening, triage, and treatment
* AIMS 2 AND 3 (WOMEN LIVING WITH HIV): Ages 25-49 years

Exclusion Criteria

* AIM 1: Stakeholder Advisory Board (SAB) members who are not engaged in CC work, individuals who have recently retired from the selected clinics, and patients who are attending the clinic for the first time will be excluded from the study
* AIMS 2 AND 3 (WOMEN LIVING WITH HIV): Pregnant women, women =\< 6 weeks postpartum, and women already confirmed to have cervical cancer will be excluded

Minimum Eligible Age

25 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael H Chung

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Chung, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Emory University Hospital/Winship Cancer Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kenya Medical Research Institute

Nairobi, , Kenya

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kenya

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amandine Zoonekyndt-Ballart

Role: CONTACT

Phone: 404-727-1210

Email: [email protected]

Mohammed K Ali, MD, MSc, MBA

Role: CONTACT

Phone: 404-727-9776

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nelly Rwamba Mugo

Role: primary